Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR 1,147.60
+3.25 (0.28%)
At close: Jul 31, 2026
Dr. Reddy's Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 331,186 | 335,933 | 325,535 | 279,164 | 245,879 | 214,391 | |
Revenue Growth | -0.92% | 3.19% | 16.61% | 13.54% | 14.69% | 13.00% |
Cost of Revenue | 165,009 | 158,669 | 135,107 | 115,557 | 106,536 | 100,551 |
Gross Profit | 166,177 | 177,264 | 190,428 | 163,607 | 139,343 | 113,840 |
Selling, General & Admin | 109,936 | 106,763 | 93,870 | 77,201 | 68,026 | 62,081 |
Research & Development | 23,580 | 24,058 | 27,380 | 22,873 | 19,381 | 17,482 |
Other Operating Expenses | -2,501 | -2,803 | -2,836 | -1,775 | -1,480 | -1,642 |
Operating Expenses | 131,015 | 128,018 | 118,414 | 98,299 | 85,927 | 77,921 |
Operating Income | 35,162 | 49,246 | 72,014 | 65,308 | 53,416 | 35,919 |
Interest Expense | -4,163 | -3,738 | -2,829 | -1,711 | -1,428 | -958 |
Interest & Investment Income | 3,597 | 3,726 | 2,677 | 2,278 | 1,180 | 965 |
Earnings From Equity Investments | 140 | 134 | 217 | 147 | 370 | 703 |
Currency Exchange Gain (Loss) | 2,152 | 1,785 | 1,322 | 278 | 2,225 | 1,835 |
Other Non Operating Income (Expenses) | 2,359 | 2,359 | 3,554 | 3,149 | 876 | 277 |
EBT Excluding Unusual Items | 39,247 | 53,512 | 76,955 | 69,449 | 56,639 | 38,741 |
Gain (Loss) on Sale of Investments | 351 | - | - | - | - | - |
Gain (Loss) on Sale of Assets | 2,955 | 2,547 | 1,522 | 900 | -1,211 | 1,119 |
Asset Writedown | -3,534 | -3,519 | -1,693 | -3 | -699 | -7,562 |
Legal Settlements | 1,400 | 1,400 | - | 1,524 | 5,638 | - |
Other Unusual Items | 877 | 877 | - | - | - | - |
Pretax Income | 41,296 | 54,817 | 76,784 | 71,870 | 60,367 | 32,298 |
Income Tax Expense | 8,578 | 12,351 | 19,539 | 16,186 | 15,300 | 8,730 |
Earnings From Continuing Operations | 32,718 | 42,466 | 57,245 | 55,684 | 45,067 | 23,568 |
Minority Interest in Earnings | 389 | 384 | -701 | - | - | - |
Net Income | 33,107 | 42,850 | 56,544 | 55,684 | 45,067 | 23,568 |
Net Income to Common | 33,107 | 42,850 | 56,544 | 55,684 | 45,067 | 23,568 |
Net Income Growth | -41.72% | -24.22% | 1.54% | 23.56% | 91.22% | 36.72% |
Shares Outstanding (Basic) | 833 | 832 | 833 | 832 | 830 | 829 |
Shares Outstanding (Diluted) | 833 | 833 | 834 | 834 | 832 | 832 |
Shares Change | -0.05% | -0.10% | 0.08% | 0.19% | 0.03% | 0.01% |
EPS (Basic) | 39.75 | 51.48 | 67.88 | 66.93 | 54.29 | 28.42 |
EPS (Diluted) | 39.72 | 51.42 | 67.78 | 66.80 | 54.17 | 28.34 |
EPS Growth | -41.68% | -24.14% | 1.47% | 23.32% | 91.16% | 36.70% |
Free Cash Flow | 21,308 | 33,429 | 18,924 | 29,030 | 47,552 | 13,448 |
Free Cash Flow Per Share | 25.57 | 40.12 | 22.69 | 34.83 | 57.16 | 16.17 |
Dividend Per Share | 8.000 | 8.000 | 8.000 | 8.000 | 8.000 | 6.000 |
Dividend Growth | 0% | 0% | 0% | 0% | 33.33% | 20.00% |
Gross Margin | 50.18% | 52.77% | 58.50% | 58.61% | 56.67% | 53.10% |
Operating Margin | 10.62% | 14.66% | 22.12% | 23.39% | 21.73% | 16.75% |
Profit Margin | 10.00% | 12.76% | 17.37% | 19.95% | 18.33% | 10.99% |
Free Cash Flow Margin | 6.43% | 9.95% | 5.81% | 10.40% | 19.34% | 6.27% |
EBITDA | 54,672 | 68,149 | 87,823 | 79,006 | 66,052 | 47,743 |
EBITDA Margin | 16.51% | 20.29% | 26.98% | 28.30% | 26.86% | 22.27% |
D&A For EBITDA | 19,510 | 18,903 | 15,809 | 13,698 | 12,636 | 11,824 |
EBIT | 35,162 | 49,246 | 72,014 | 65,308 | 53,416 | 35,919 |
EBIT Margin | 10.62% | 14.66% | 22.12% | 23.39% | 21.73% | 16.75% |
Effective Tax Rate | 20.77% | 22.53% | 25.45% | 22.52% | 25.35% | 27.03% |